The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies Jens U. MarquardtAnna SaborowskiArndt Vogel Review Article 25 February 2019 Pages: 115 - 123
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies Fabienne LucasJennifer A. Woyach Review Article 30 March 2019 Pages: 125 - 138
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis Qianqian GuoXiaojie LinQianjun Chen Systematic Review 03 April 2019 Pages: 139 - 148
Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study Xiaonan HongYuqin SongChunxiao Cai Original Research Article Open access 23 March 2019 Pages: 149 - 158
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib Yudong SuXiang LongNaixin Liang Original Research Article 20 March 2019 Pages: 159 - 168
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib Yiming ZhaoShuyuan WangBaohui Han Original Research Article 19 March 2019 Pages: 169 - 178
Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy Toshio TakagiHironori FukudaKazunari Tanabe Original Research Article 29 March 2019 Pages: 179 - 186
Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors Xiang ChenJiaXi YaoJianMing Guo Original Research Article 18 March 2019 Pages: 187 - 195
EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR Anna BuderUlrike SetinekMartin Filipits Original Research Article Open access 27 February 2019 Pages: 197 - 203
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System Emanuel RaschiAlessandra MazzarellaFabrizio De Ponti Original Research Article 29 March 2019 Pages: 205 - 221
Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models Pei San YeeNur Syafinaz ZainalSok Ching Cheong Original Research Article 26 February 2019 Pages: 223 - 235
Rucaparib: A Review in Ovarian Cancer Matt Shirley Adis Drug Evaluation 04 March 2019 Pages: 237 - 246